NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
Loading market information…
NSE · AGARWALEYE.NS · INR
Stock price, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Dr. Agarwal's Health Care Limited’s quoted price sits in the upper half of its reported 52-week range, 10.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dr. Agarwal's Health Care Limited’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of ₹1.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dr. Agarwal's Health Care Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dr. Agarwal's Health Care Limited manages a chain of eye hospitals both within India and abroad. The company delivers a comprehensive range of ophthalmic services, including advanced surgical solutions for cataracts like small incision, phacoemulsification, robotic, and glued intraocular lens procedures. It also offers refractive surgeries designed to correct visual errors, thereby lessening or removing the necessity for glasses and contact lenses. Additional surgical specialties include treatments for retinal conditions, corneal transplantation, pinhole pupilloplasty, oculoplasty, and operations for glaucoma and pterygium. Beyond surgical interventions, the company provides professional medical consultations, in-depth diagnostic services for various eye disorders, and non-surgical therapies such as retinal laser treatment and dry eye management. Furthermore, Dr. Agarwal's Health Care Limited sells optical goods, including spectacles, lenses, contact lenses, and frames, as well as a variety of pharmaceutical products for eye care. The company was founded in 2010 and is based in Chennai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | May 28, 2025 | ₹1.10+22.22% vs estimate | ₹4.60B-8.71% vs estimate |
|---|
| Q3 2025 | Feb 14, 2025 | ₹0.70 | ₹4.31B |
|---|
| Q2 2025 | Jun 30, 2024 | ₹0.50 | ₹4.10B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
₹9,780.00+₹116.00 (+1.2%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
₹4,613.40+₹33.40 (+0.73%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
₹2,405.50+₹161.50 (+7.2%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹1,245.50+₹61.10 (+5.16%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
₹8,448.00+₹248.00 (+3.02%)
Apollo Hospitals Enterprise Limited’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
₹5,280.15+₹3.35 (+0.06%)
Dr. Agarwal's Eye Hospital Limited’s quoted price sits in the lower half of its reported 52-week range, 17.39% below the high.
₹109.15-₹0.85 (-0.77%)
Lotus Eye Hospital and Institute Limited’s quoted price sits in the lower half of its reported 52-week range, 25.75% below the high.
